Details of the Drug Pharmacogenomic Perturbation Atlas

Methylergonovine Drug Info

Basofortina; Ergotyl; Metenarin; Methergen; Methergin; Methergine; Methylergobasin; Methylergobasine; Methylergobrevin; Methylergometrin; Methylergometrine; Methylergometrinum; Methylergonovin; Metilergometrina; Metilergometrinio; Partergin; Ryegonovin; Lysergic acid butanolamide; Methylergometrine maleate; Metilergometrina [DCIT]; ME 277; Ergotyl (TN); Methergine (TN); Methylergometrine (INN); Methylergometrine [INN:BAN]; Methylergometrinum [INN-Latin]; Metilergometrinio [INN-Spanish]; Spametrin-M; D-Lysergic acid-dl-hydroxybutylamide-2; N-(alpha-(Hydroxymethyl)propyl)-D-lysergamide; D-Lysergic acid-(+)-butanolamide-(2); (8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-6-methyl-9,10-didehydroergoline-8-carboxamide; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-6-methylergoline-8-carboxamide; 9,10-Didehydro-N-(alpha-(hydroxymethyl)propyl)-6-methyl-ergoline-8-beta-carboxamide

Therapeutic Class

Cross-matching ID

PubChem CID

8226

ChEBI ID

CHEMBL1201356

CAS Number

CAS 113-42-8

TTD Drug ID

D05AHE

VARIDT Drug ID

DR00997

INTEDE Drug ID

DR1052

ACDINA Drug ID

D00418

General Information of Drug (ID: DMBEX4O)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Systemic lupus erythematosus	2.21	0.00e+0	45/135 (33.33%)	C1S;C3;IFNG;...
Graft-versus-host disease	2.03	4.78e-3	32/42 (76.19%)	GZMB;IFNG;HLA-DRB1;...
Metabolism of xenobiotics by cytochrome P450	1.97	3.19e-3	49/77 (63.64%)	EPHX1;ADH1B;CYP2E1;...
Asthma	1.97	2.39e-3	25/31 (80.65%)	PRG2;HLA-DRB1;HLA-DMB;...
Allograft rejection	1.95	1.91e-3	32/38 (84.21%)	GZMB;IFNG;HLA-DRB1;...
Intestinal immune network for IgA production	1.91	6.38e-3	38/48 (79.17%)	CXCL12;TNFRSF17;HLA-DRB1;...
Viral protein interaction with cytokine and cytokine re...	1.87	1.23e-2	84/100 (84%)	CCL19;CXCL9;CXCL13;...
Glycolysis / Gluconeogenesis	1.85	1.32e-2	56/67 (83.58%)	PCK2;ADH1B;ENO2;...
Retinol metabolism	1.78	1.70e-2	41/68 (60.29%)	ALDH1A1;ADH1B;ALDH1A2;...
Protein digestion and absorption	1.77	1.63e-2	78/103 (75.73%)	COL21A1;COL15A1;COL6A3;...
Autoimmune thyroid disease	1.73	2.78e-2	46/53 (86.79%)	GZMB;HLA-DRB1;HLA-DMB;...
Complement and coagulation cascades	1.71	3.43e-2	76/85 (89.41%)	CFH;C1S;C3;...
Rheumatoid arthritis	1.69	3.68e-2	78/93 (83.87%)	CXCL12;VEGFA;CCL5;...
Glycine, serine and threonine metabolism	1.68	4.03e-2	31/40 (77.5%)	PSAT1;CTH;GATM;...
Steroid biosynthesis	-1.94	3.15e-2	19/20 (95%)	TM7SF2;HSD17B7;EBP;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H, 24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H

Prostate

Prostate carcinoma

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H, 24H